Drug

MTOR Kinase Inhibitor AZD8055

CI-DRUG-00000365Explore in graph →NCIt C78856 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase1	Phase 1	5	—	—	2008-07
Malignant Central Nervous System Neoplasm	Phase1	Phase 1	1	—	—	Mar 4, 2011
Malignant Liver Neoplasm	Phase1	Phase 1	1	—	—	2009-10

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RICTOR Amplification1
MTOR Kinase Inhibitor AZD8055

Clinical trials

Trials with this intervention (5)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–5 of 5 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01316809	AZD8055 for Adults With Recurrent Gliomas	completed	Phase 1	22	National Cancer Institute (NCI)NIH	1	Dec 12, 2019	clinicaltrials
NCT00731263	A Study of Tor Kinase Inhibitor in Advanced Tumors	completed	Phase 1	64	AstraZeneca

MTOR A2034V1
MTOR Kinase Inhibitor AZD8055 + RapaLink-1Substitutes	Malignant Breast Neoplasm	Predictive	D	Does Not Support Resistance	4	accepted	EID1548 MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling w… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC	civic

MTOR A2034V1

MTOR Kinase Inhibitor AZD8055 + RapaLink-1Substitutes

Malignant Breast Neoplasm

Predictive

Does Not Support Resistance

accepted

EID1548

MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling w… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

civic

MTOR M2327I1
MTOR Kinase Inhibitor AZD8055	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID1544 MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling w… (full text at CIViC) PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC	civic

MTOR M2327I1

MTOR Kinase Inhibitor AZD8055

Malignant Breast Neoplasm

Predictive

Supports Resistance

accepted

EID1544

MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling w… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

civic

HRAS G12V + HRAS Q61L + HRAS Q61R1
Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID700 In preclinical cancer cell line and Ba/F3 models, HRAS Q61L, Q61R, and G12V mutations conferred sensitivity to MEK inhibitors (AZD6244/selumetinib, MEK162/binimetinib, and PD0325901) and mTOR inhibito… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC	civic

HRAS G12V + HRAS Q61L + HRAS Q61R1

Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID700

In preclinical cancer cell line and Ba/F3 models, HRAS Q61L, Q61R, and G12V mutations conferred sensitivity to MEK inhibitors (AZD6244/selumetinib, MEK162/binimetinib, and PD0325901) and mTOR inhibito… (full text at CIViC)

PMID 26544513 · Kiessling et al., 2015 · Open in CIViC

civic